QUICKLINKS AND VIEW OPITONS

EMAIL THE ARTICLE BELOW TO A FRIEND

Email address of your friend:
(For example: myfriend@aol.com)

Your name:
(Example: Lori Jones)

Your email address:
(For example: lorijones@aol.com)

Subject:

Message:
Here is a summary of article I thought you might be interested in. Risk of suicide caused by SSRI’s grossly underestimated, Peter Gotzsche, MD “It is clear that the risk of suicide caused by SSRIs has been grossly underestimated in the trials, and there are many reasons for this,” writes Prof. Peter C. Gotzsche, MD in Chapter 16 What can patients do? of his excellent book Deadly Psychiatry and Organised Denial. “Fraud. “The investigators didn’t report suicide attempts or didn’t even look for them. “Many suicidal events have been coded as something else. “By only recruiting people at very low risk of committing suicide for their trials, the drug industry has taken great care not to get in trouble. “The companies have urged investigators to use benzodiazepines in addition to the trial drugs, which have prevented some of the violent reactions that would otherwise have occurred. “Some trials have run-in periods on active drug, and patients who don’t tolerate it aren’t randomised. “Most patients were in antidepressant treatment before they were randomised, which leads to withdrawal symptoms in the placebo group that predispose to suicide. “Events occurring shortly after active treatment is stopped were rarely registered. “Many trials are buried in company archives and these are not the most positive ones. “Patients are carefully monitored in trials and drug intake is likely to be stopped before a serious problem develops. “Patients in trials have contact with other people and get hope, therefore the risk of suicide is less than in real life.” Here is the link to the entire article. http://www.fatnews.com/index.php/5828

Risk of suicide caused by SSRI’s grossly underestimated, Peter Gotzsche, MD

“It is clear that the risk of suicide caused by SSRIs has been grossly underestimated in the trials, and there are many reasons for this,” writes Prof. Peter C. Gotzsche, MD in Chapter 16 What can patients do? of his excellent book Deadly Psychiatry and Organised Denial.

“Fraud.

“The investigators didn’t report suicide attempts or didn’t even look for them.

“Many suicidal events have been coded as something else.

“By only recruiting people at very low risk of committing suicide for their trials, the drug industry has taken great care not to get in trouble.

“The companies have urged investigators to use benzodiazepines in addition to the trial drugs, which have prevented some of the violent reactions that would otherwise have occurred.

“Some trials have run-in periods on active drug, and patients who don’t tolerate it aren’t randomised.

“Most patients were in antidepressant treatment before they were randomised, which leads to withdrawal symptoms in the placebo group that predispose to suicide.

“Events occurring shortly after active treatment is stopped were rarely registered.

“Many trials are buried in company archives and these are not the most positive ones.

“Patients are carefully monitored in trials and drug intake is likely to be stopped before a serious problem develops.

“Patients in trials have contact with other people and get hope, therefore the risk of suicide is less than in real life.”

Posted by: Admin2 on Nov 27, 2015 - 3:30 am

© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.

SEARCH THIS SITE

CONTACT US

CATEGORIES

ARCHIVES

ARCHIVE SUMMARY

RSS / XML

QUICKLINKS AND VIEW OPITONS

EMAIL THE ARTICLE BELOW TO A FRIEND

Risk of suicide caused by SSRI’s grossly underestimated, Peter Gotzsche, MD